• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by NanoViricides, Inc.

    NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
    From NanoViricides, Inc.
    Via AccessWire
    Topics Regulatory Compliance
    Exposures COVID-19 Legal Regulatory
    Tickers NNVC
    NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
    From NanoViricides, Inc.
    Via AccessWire
    Exposures COVID-19
    Tickers NNVC
    NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
    From NanoViricides, Inc.
    Via AccessWire
    Exposures COVID-19
    Tickers NNVC
    NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
    From NanoViricides, Inc.
    Via AccessWire
    Topics Regulatory Compliance
    Exposures COVID-19 Legal Regulatory
    Tickers NNVC
    NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
    From NanoViricides, Inc.
    Via AccessWire
    Topics Regulatory Compliance
    Exposures COVID-19 Legal Product Safety
    Tickers NNVC
    NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
    From NanoViricides, Inc.
    Via AccessWire
    Exposures COVID-19 Product Safety
    Tickers NNVC
    NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
    From NanoViricides, Inc.
    Via AccessWire
    Topics Intellectual Property Regulatory Compliance
    Exposures COVID-19 Intellectual Property Legal
    Tickers NNVC
    NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
    From NanoViricides, Inc.
    Via AccessWire
    Exposures COVID-19 Product Safety
    Tickers NNVC
    NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND
    From NanoViricides, Inc.
    Via AccessWire
    Topics Regulatory Compliance
    Exposures COVID-19 Legal Product Safety
    Tickers NNVC
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.